Prestige Consumer Healthcare Inc. (NYSE:PBH) Position Increased by Xponance Inc.

Xponance Inc. increased its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 10.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,570 shares of the company’s stock after buying an additional 328 shares during the quarter. Xponance Inc.’s holdings in Prestige Consumer Healthcare were worth $279,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC grew its position in shares of Prestige Consumer Healthcare by 3.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company’s stock worth $126,274,000 after acquiring an additional 49,331 shares during the last quarter. Geode Capital Management LLC grew its position in Prestige Consumer Healthcare by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after purchasing an additional 50,961 shares during the last quarter. Congress Asset Management Co. increased its stake in shares of Prestige Consumer Healthcare by 5.0% in the fourth quarter. Congress Asset Management Co. now owns 908,742 shares of the company’s stock valued at $70,964,000 after purchasing an additional 43,619 shares during the period. Boston Trust Walden Corp raised its holdings in shares of Prestige Consumer Healthcare by 43.5% during the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock valued at $64,942,000 after buying an additional 252,089 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Prestige Consumer Healthcare by 5.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company’s stock worth $49,667,000 after buying an additional 33,844 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently commented on PBH shares. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Canaccord Genuity Group lifted their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Royal Bank of Canada increased their target price on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a “sector perform” rating in a research report on Friday, March 21st. Oppenheimer boosted their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. Finally, Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a report on Monday, December 9th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $93.33.

Prestige Consumer Healthcare Price Performance

NYSE PBH opened at $86.07 on Friday. Prestige Consumer Healthcare Inc. has a 1 year low of $62.35 and a 1 year high of $90.04. The business’s fifty day moving average is $83.17 and its two-hundred day moving average is $78.89. The stock has a market capitalization of $4.26 billion, a P/E ratio of 20.16, a P/E/G ratio of 2.69 and a beta of 0.46. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares of the company’s stock, valued at $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 1.60% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.